Canagliflozin treatment in patients with type 2 diabetes mellitus

Curtis Triplitt, Susan Cornell

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


Current guidelines for treatment of type 2 diabetes mellitus (T2DM) indicate a patient-centered approach that should go beyond glycemic control. Of the many antihyperglycemic agents available for treatment of T2DM, sodium-glucose cotransporter 2 (SGLT2) inhibitors offer the advantages of reduced glycated hemoglobin (A1C), body weight (BW), and systolic blood pressure (SBP) and are associated with a low risk of hypoglycemia when used either as monotherapy or with other agents not typically associated with increased risk of hypoglycemia. Collaborative, multidisciplinary teams are best suited to provide care to patients with diabetes, and clinical pharmacists can enhance the care provided by these teams. This review aims to provide insight into the mode of action, pharmacology, potential drug–drug interactions, clinical benefits, and safety considerations associated with use of the SGLT2 inhibitor canagliflozin in patients with T2DM and to provide information to enhance clinical pharmacists’ understanding of canagliflozin.

Original languageEnglish (US)
Article numberA012
Pages (from-to)73-81
Number of pages9
JournalClinical Medicine Insights: Endocrinology and Diabetes
StatePublished - 2015


  • Canagliflozin
  • SGLT2 inhibitors
  • Treatment goals
  • Type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Canagliflozin treatment in patients with type 2 diabetes mellitus'. Together they form a unique fingerprint.

Cite this